Skip to main content
Skip to main navigation
Search for :
Product Development Strategy
Early Clinical Development
Phase I/IIa Clinical Trials
Phase II/III Clinical Trials
Interventional Phase IIIb/Phase IV Clinical Trials
Observational Research & Registries
Product Launch & Management
Market Access Solutions
Strategic Sales Outsourcing
Biopharmaceutical Sales & Marketing
Healthcare Payers & Providers
Medical Device & Diagnostics
Public Health & Government
Central Nervous System
Diabetes & Endocrinology
Early Phase Oncology
Public Health Interest
Other Therapeutic Areas
Ethics & Compliance
White Paper - November 2, 2010 - pdf
By: Kelly T. McKee Jr., M.D., M.P.H.
Select one of the options below to save this article to your library.
After decades of work mapping the human genome, we are beginning to reap real benefits through the tools of pharmacobiomics. Particularly in the area of infectious disease, biomics is shedding new light on how disease originates and how the individual immune system responds. Working in conjunction with biomarkers, these new technologies are increasing the ability to diagnose, monitor and manage infections.
Dr. Kelly McKee explores the multi-faceted research in pharmacobiomics and how it will shape the future of pharma and biotech product development. Every new bit of knowledge is leading to more effective approaches to drug and vaccine development — improving product effectiveness as well as delivering process efficiencies.
About the Author
Kelly T. McKee Jr., M.D., M.P.H.Vice President, Public Health and Government Services, Quintiles
Dr. McKee has dedicated his career to researching and preventing infectious diseases. Before joining Quintiles in 2006, he served as Senior Director of Clinical Research and Chief Medical Officer for a vaccine development company. After finishing a 20-year career in the U.S. Army Medical Department, he served as the Head of General Communicable Disease Control and State Epidemiologist for North Carolina, but returned to government work at the U.S. Army Medical Research Institute of Infectious Diseases (USAMRIID). He has written over 100 peer-reviewed publications and textbook chapters and reviews manuscripts for several professional journals.